A citation-based method for searching scientific literature

Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Kostandinos Sideras, John C Morris, Bryan McIver, Jill K Burton, Kevin P Webster, Carolyn Bieber, Anne M Traynor, Patrick J Flynn, Boon Cher Goh, Hui Tang, Susan Percy Ivy, Charles Erlichman. Lancet Oncol 2010
Times Cited: 308







List of co-cited articles
1193 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
877
80

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
73

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L Carr, David A Mankoff, Bernardo H Goulart, Keith D Eaton, Peter T Capell, Elizabeth M Kell, Julie E Bauman, Renato G Martins. Clin Cancer Res 2010
287
55

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
244
53

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Francis P Worden, Madeleine A Kane, Eric Sherman, Sinil Kim, Paul Bycott,[...]. J Clin Oncol 2008
464
49

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
47

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
483
45

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
951
45

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
186
35

Motesanib diphosphate in progressive differentiated thyroid cancer.
Steven I Sherman, Lori J Wirth, Jean-Pierre Droz, Michael Hofmann, Lars Bastholt, Renato G Martins, Lisa Licitra, Michael J Eschenberg, Yu-Nien Sun, Todd Juan,[...]. N Engl J Med 2008
357
33

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
877
33

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
685
32

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Steven G Waguespack, Maria E Cabanillas, Steven I Sherman, Bo Ma, Martin Curtis,[...]. Thyroid 2015
128
31


Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
S Michael Rothenberg, David G McFadden, Edwin L Palmer, Gilbert H Daniels, Lori J Wirth. Clin Cancer Res 2015
178
28

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah. J Clin Oncol 2017
75
37

Definition and management of radioactive iodine-refractory differentiated thyroid cancer.
Martin Schlumberger, Marcia Brose, Rosella Elisei, Sophie Leboulleux, Markus Luster, Fabian Pitoia, Furio Pacini. Lancet Diabetes Endocrinol 2014
183
25

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Laura D Locati, Lisa Licitra, Laura Agate, Sai-Hong I Ou, Andree Boucher, Barbara Jarzab, Shukui Qin, Madeleine A Kane, Lori J Wirth, Connie Chen,[...]. Cancer 2014
74
33

Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, Kathy Ransone, Susan J Mandel, Keith T Flaherty, Laurie A Loevner, Peter J O'Dwyer,[...]. J Clin Oncol 2008
502
24

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein,[...]. Eur J Cancer 2017
66
36

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Maria E Cabanillas, Martin Schlumberger, Barbara Jarzab, Renato G Martins, Furio Pacini, Bruce Robinson, Judith C McCaffrey, Manisha H Shah, Donald L Bodenner, Duncan Topliss,[...]. Cancer 2015
123
23

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Nina Karlin, Kostandinos Sideras, John C Morris,[...]. J Clin Endocrinol Metab 2014
73
30

Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Athanasios Bikas, Priya Kundra, Sameer Desale, Mihriye Mete, Kaitlyn O'Keefe, Brandon G Clark, Lynette Wray, Rahul Gandhi, Christina Barett, James S Jelinek,[...]. Eur J Endocrinol 2016
39
56


New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
21

Phase II trial of sorafenib in metastatic thyroid cancer.
Richard T Kloos, Matthew D Ringel, Michael V Knopp, Nathan C Hall, Mark King, Robert Stevens, Jiachao Liang, Paul E Wakely, Vasyl V Vasko, Motoyasu Saji,[...]. J Clin Oncol 2009
403
21

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
574
21

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
385
21

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
Keith C Bible, Vera J Suman, Michael E Menefee, Robert C Smallridge, Julian R Molina, William J Maples, Nina J Karlin, Anne M Traynor, Priya Kumar, Boon Cher Goh,[...]. J Clin Endocrinol Metab 2012
111
20

A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
S M Lim, H Chang, M J Yoon, Y K Hong, H Kim, W Y Chung, C S Park, K H Nam, S W Kang, M K Kim,[...]. Ann Oncol 2013
94
21

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Martin Schlumberger, Barbara Jarzab, Maria E Cabanillas, Bruce Robinson, Furio Pacini, Douglas W Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G Martins,[...]. Clin Cancer Res 2016
138
19

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Glenn J Hanna, Naifa L Busaidy, Nicole G Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits,[...]. Clin Cancer Res 2018
49
38

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
Maria E Cabanillas, Marcia S Brose, Jaymes Holland, Kimberly C Ferguson, Steven I Sherman. Thyroid 2014
50
36

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Merina Ahmed, Yolanda Barbachano, Angela Riddell, Jen Hickey, Katie L Newbold, Amaya Viros, Kevin J Harrington, Richard Marais, Christopher M Nutting. Eur J Endocrinol 2011
153
17


Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
Ramona Dadu, Catherine Devine, Mike Hernandez, Steven G Waguespack, Naifa L Busaidy, Mimi I Hu, Camilo Jimenez, Mouhammad A Habra, Rena V Sellin, Anita K Ying,[...]. J Clin Endocrinol Metab 2014
65
26

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
372
16

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A Knauf, Xiao-Hui Liao, Brian L West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen,[...]. J Clin Invest 2011
235
16

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
D Neil Hayes, Amy S Lucas, Tawee Tanvetyanon, Monika K Krzyzanowska, Christine H Chung, Barbara A Murphy, Jill Gilbert, Ranee Mehra, Dominic T Moore, Arif Sheikh,[...]. Clin Cancer Res 2012
112
16

An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Sun Min Lim, Woong Youn Chung, Kee-Hyun Nam, Sang-Wook Kang, Jae Yun Lim, Hoon-Gu Kim, Seong Hoon Shin, Jong-Mu Sun, Seong-Geun Kim, Joo-Hang Kim,[...]. Eur J Cancer 2015
34
47

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Eric J Sherman, Lara A Dunn, Alan L Ho, Shrujal S Baxi, Ronald A Ghossein, Matthew G Fury, Sofia Haque, Cami S Sima, Grace Cullen, James A Fagin,[...]. Cancer 2017
44
36

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
Richard J Robbins, Qiang Wan, Ravinder K Grewal, Roland Reibke, Mithat Gonen, H William Strauss, R Michael Tuttle, William Drucker, Steven M Larson. J Clin Endocrinol Metab 2006
361
15

Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Marie-Hélène Massicotte, Maryse Brassard, Médéric Claude-Desroches, Isabelle Borget, Françoise Bonichon, Anne-Laure Giraudet, Christine Do Cao, Cécile N Chougnet, Sophie Leboulleux, Eric Baudin,[...]. Eur J Endocrinol 2014
71
19

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, Arlene A Forastiere, Roger B Cohen, Ranee Mehra, David G Pfister, Ezra E W Cohen, Linda Janisch, Forlisa Nauling,[...]. J Clin Oncol 2011
416
14


Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Tatiana C Schneider, Djoeke de Wit, Thera P Links, Nielka P van Erp, Jakobus J M van der Hoeven, Hans Gelderblom, Inge C F M Roozen, Manon Bos, Wim E Corver, Tom van Wezel,[...]. J Clin Endocrinol Metab 2017
52
26

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Janice M Mehnert, Andrea Varga, Marcia S Brose, Rahul R Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A Piha-Paul,[...]. BMC Cancer 2019
85
16

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
276
13

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
13

Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Jaume Capdevila, José Manuel Trigo, Javier Aller, José Luís Manzano, Silvia García Adrián, Carles Zafón Llopis, Òscar Reig, Uriel Bohn, Teresa Ramón Y Cajal, Manuel Duran-Poveda,[...]. Eur J Endocrinol 2017
21
61


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.